key: cord-0897041-axpqom85
authors: Lamb, Laura E.; Dhar, Nivedita; Timar, Ryan; Wills, Melissa; Dhar, Sorabh; Chancellor, Michael B.
title: COVID-19 Inflammation Results in Urine Cytokine Elevation and Causes COVID-19 Associated Cystitis (CAC)
date: 2020-11-05
journal: Med Hypotheses
DOI: 10.1016/j.mehy.2020.110375
sha: 8badb2c9d3220693cbda741640ac6b6b01783c83
doc_id: 897041
cord_uid: axpqom85

Coronavirus disease 2019 (COVID-19) causes a wide range of symptoms, including several unexpected symptoms such as loss of taste, skin changes, and eye problems. We recently observed patients with documented COVID-19 develop de novo severe genitourinary symptoms, most notably urinary frequency of ≥ 13 episodes/24 hours and nocturia ≥ 4 episodes/night. We call these associated urinary symptoms COVID-19 associate cystitis (CAC). COVID-19 severity is associated with inflammation. We collected urine samples from COVID-19 patients, including patients with CAC, and found elevation of proinflammatory cytokines also in the urine. It has been previously shown that patients with urinary incontinence and ulcerative interstitial cystitis/bladder pain syndrome have elevated urinary inflammatory cytokines compared to normal controls. We therefore hypothesize that CAC, with presentation of de novo severe urinary symptoms, can occur in COVID-19 and is caused by increased inflammatory cytokines that are released into the urine and/or expressed in the bladder. The most important implications of our hypothesis are: 1) Physician caring for COVID-19 patients should be aware of COVID-19 associate cystitis (CAC); 2) De novo urinary symptoms should be included in the symptom complex associated with COVID-19; and 3) COVID-19 inflammation may result in bladder dysfunction.

Syndrome Coronavirus-2 (SARS-CoV-2) virus, can cause a wide range of symptoms with the most common being fever, dry cough, and tiredness. Other symptoms may include headache, sore throat, shortness of breath or difficulty breathing, muscle aches, or chills. However, COVID-19 can also result in unexpected symptoms including loss of taste or small, itchy lesions on hands and feet, swollen eyelids and increase eye discharge, and gastrointestinal symptoms, including a loss of appetite, nausea, vomiting and diarrhea. Recently, Mumm and colleagues reported increased urinary frequency in COVID-19 patients (1). We also observed confirmed COVID-19 patients develop de novo severe genitourinary symptoms, most notably urinary frequency of > 13 episodes/24 hours and nocturia > 4 episodes/night (2) . Some patients also noted pain or discomfort associated with urination. We have called these associated urinary symptoms COVID-19 associate cystitis (CAC).

Since COVID-19 severity is associated with inflammation and increased inflammatory cytokines, we then examined expression of inflammatory cytokines in the urine of these COVID-19 patients. We observed that the urine of confirmed COVID-19 patients had elevated levels of pro-inflammatory cytokines.

We hypothesize that CAC, with presentation of de novo severe urinary symptoms, can occur in COVID-19 patients and is caused by increased inflammatory cytokines that are released into the urine and/or expressed in the bladder (Figure 1 ). We further hypothesize that chronic COVID-19

Associated Cystitis may occur in COVID-19 patients who do not fully recover and have a chronic inflammatory condition ongoing. There have been reports that inflammatory cytokines are elevated in the urine in urinary incontinent and interstitial cystitis/bladder pain syndrome patients compared to normal controls (6) (7) (8) (9) (10) (11) . For example, in overactive bladder (OAB), urinary cytokines elevated in OAB patients compared to controls included monocyte chemotactic protein-1 (MCP-1), soluble fraction of the CD40 ligand (sCD40L), macrophage inflammatory protein (MIP-1β), IL-12p70/p40, IL-5, epidermal growth factor (EGF), growth-related oncogene GRO-α, sIL-2Rα, and IL-10 (8). The bladder tissue of interstitial cystitis patients compared to controls have increased IL-16, IL-18, CTACK, ICAM-1, MCP-3, SCGFβ, TRAIL, and VCAM-1 (7). Urinary cytokines are also elevated in interstitial cystitis with Hunner's lesions, specifically IL-6, IL-8, and GRO (6).

Cystitis, or bladder inflammation, can cause bladder dysfunction (12, 13) . Inflammation can occur from pathogenic (bacterial or viral), non-pathogenic (i.e. radiation, medication, chemicals, etc.), or idiopathic (i.e. interstitial cystitis) causes. Pro-inflammation mediators, including cytokines, can damage and irritate the bladder mucosa, the bladder tissue that is in contact with urine (12, 13) .

The bladder mucosa is a dynamic sensory structure that can sense bladder fullness and can modulate bladder nerve and muscle function. Inflammation damage to the mucosa can thus result in bothersome lower urinary tract symptoms as the damaged urothelium may activate afferent nerves as well as locally influence bladder muscle function (12, 13) . Infection with SARS-CoV-2 in some can result in systemic inflammation and abnormally high immunologic response is associated with more severe COVID-19 symptoms and outcomes, including death (14) (15) (16) . This has been referred to as the cytokine storm syndrome or cytokine release syndrome. Increased expression of cytokines, especially IL-6, IL-1β, C-reactive protein, and TNF-α, are detectable in serum of COVID-19 patients with IL-6 being the best single prognostic indicator of COVID-19 severity (17) .

In our observations detailed below, we have observed that several cytokines are elevated and detectable in the urine of COVID-19 patients with CAC. The presence of these cytokines in the urine could impact bladder sensation and thus function, resulting in the observed increased urinary frequency and nocturia. It is also possible that the virus may directly damage the bladder tissue, impacting bladder function. Lastly, impaired kidney function may cause some of the symptoms observed with CAC.

If our hypothesis is correct, we predict that drugs that are useful in helping treat overactive bladder may also be considered in CAC. Given that rest and sleep are important during illness for recovery, improving nocturia and frequency could help improve the speed and quality of recovery of COVID-19 patients. Furthermore, monitoring urinary cytokines may serve as a prognostic indicator for COVID-19 progression and severity when serum collection is not feasible or practical. positive CAC patients had de novo urological symptoms of urinary urgency (4/4), urge incontinence (4/4) and urinary frequency/24 hrs of 11-12 episodes (n=1), 13-14 episodes (n=1) and 15+ episodes/24 hrs (n=2). All COVID-19 patients report de novo nocturia of 3, (n=1), 4 (n=2) and 5 episodes/night (n=1). All COVID-19 positive patients had elevated levels of inflammatory cytokines IL-6, IL-8, and IP-10 in their urine compared to COVID-19 negative patients, with IL-6 and IL-8 being statistically significant (Table 1) . There was variance between individuals that may reflect the severity and duration of their disease, and/or the presence of comorbidities. This data supports that COVID-19 patients with CAC have increased inflammatory cytokines in the urine.

We propose that COVID-19 Associate Cystitis (CAC), with presentation of de novo severe urinary symptoms, can occur in COVID-19 and is caused by increased inflammatory cytokines that are released into the urine and/or expressed in the bladder. The most important implications of our hypothesis are: 1) Physicians and other clinicians caring for COVID-19 patients should be aware of CAC; 2) De novo urinary symptoms should be included in the symptoms complex associated with COVID-19; and 3) COVID-19 inflammation may result in bladder dysfunction. We further hypothesize that chronic COVID-19 Associated Cystitis may occur in COVID-19 patients who do not fully recover and have a chronic inflammatory condition ongoing.

The authors would like to thank Dr. Bernadette Zwaans, Sarah Bartolone, and Elijah Ward for their critical review of the manuscript.

Declaration of Competing Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Table 1 . Cytokine expression in urine of asymptomatic controls (n=4) and COVID-19 patients with de novo urinary symptoms (n=4). SEM=Standard error mean. P-value calculated from a onetailed, two-sample T test with unequal variances.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. 

authorship contribution statement: Laura E. Lamb: Conceptualization, Methodology, Formal Analysis, Investigation, Data Curation, Resources, Writing -original draft, Writing -review &editing. Nivedita Dhar: Conceptualization, Investigation, Resources, Writing -review &editing

Chancellor: Conceptualization, Writing -review &editing, Supervision. Melissa Wills and Ryan Timar: Data collection and processing

De Novo Urinary Symptoms Associated with COVID-19: COVID-19 Associated Cystitis (CAC)

HIV status is an independent risk factor for reporting lower urinary tract symptoms. The Journal of urology

Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers

Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation

Pubmed Central PMCID: PMC5663335 methods for diagnosing interstitial cystitis. All other authors have declared no conflicts of interest exist. This does not alter our adherence to PLOS ONE policies on sharing data and materials

Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. World journal of urology

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study

Alteration of Urothelial Inflammation, Apoptosis, and Junction Protein in Patients with Various Bladder Conditions and Storage Bladder Symptoms Suggest Common Pathway Involved in Underlying Pathophysiology. Lower urinary tract symptoms

Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis

HB-EGF, and EGF biomarkers in patients with ulcerative vs. non-ulcerative interstitial cystitis

Role of inflammation in bladder function and interstitial cystitis

The Role of the Mucosa in Normal and Abnormal Bladder Function

Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

The potential role of IL-6 in monitoring severe case of coronavirus disease